Hookworm peptide therapeutic for oral treatment of IBD (Old ID 26317)

Chief Investigator

We intend to develop an orally delivered peptide that can modulate the immune system and be developed as a therapeutic for inflammatory bowel disease. We have identified a peptide, derived from a hookworm protein, that alleviates the clinical symptoms of experimental colitis when orally administered to mice. The peptide has bioactivity with human cells ex vivo and displays desirable drug-like properties. The aim of this project is to acquire further data on the mechanism of action and formulation conditions to facilitate formal product development prior to licensing and clinical trials.

01 Jan 2020 - 30 Jun 2022

N/A